Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study

Nabila Kazmi, Elena V. Valeeva, Gulshat R. Khasanova, Sarah J Lewis, Denis Plotnikov*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)


Background Observational studies have found some evidence of an association between elevated blood pressure and pros-tate cancer risk; however, the results are inconclusive. We tested whether systolic blood pressure (SBP) influences prostate cancer risk and evaluated the effect of calcium channel blockers (CCB) on the disease using Mendelian randomization (MR) approach.Methods We used 278 genetic variants associated with SBP and 16 genetic variants in CCB genes as instrumental variables. Effect estimates were obtained from the UK Biobank sample of 142,995 males and from PRACTICAL consortium (79,148 cases and 61,106 controls).Results For each 10mm Hg increase in SBP the estimated effect was OR 0.96 (0.90–1.01) for overall prostate cancer; and OR 0.92 (0.85–0.99) for aggressive prostate cancer. The MR-estimated effect of a 10mm Hg- SBP lowering through CCB genetic variants was OR 1.22 (1.06–1.42) for all prostate cancers and OR 1.49 (1.18–1.89) for aggressive prostate cancer.Conclusion The results of our study did not support a causal relationship between SBP and prostate cancer; however, we found weak evidence of a protective effect of high SBP on aggressive prostate cancer and we found that blocking calcium channel receptors may increase prostate cancer risk
Original languageEnglish
Pages (from-to)725–734
Number of pages10
JournalCancer Causes and Control
Issue number8
Publication statusPublished - 13 May 2023

Bibliographical note

Funding Information:
NKs salary is funded by a research grant from the World Cancer Research Fund (IIG_FULL_2020_01). SJL is supported by a Cancer Research UK 25 (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme).

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Structured keywords

  • ICEP


  • Blood pressure
  • prostate cancer
  • Mendelian randomization
  • calcium channel blockers


Dive into the research topics of 'Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study'. Together they form a unique fingerprint.

Cite this